Employing A Functional Service Provider (FSP) Partnerships Model In Non-Footprint Countries: Trends, Challenges, And Solutions

Maintaining a robust global presence has become a pressing demand in clinical trials, pushing teams to expand operations across different geographic regions. This initiative provides several advantages, including access to a more diverse clinical trial population, in-country regulatory expertise, proactive risk mitigation, and the ability to overcome competition for research sites and participants in a burgeoning research environment.

However, for many biotechnology and biopharmaceutical companies, establishing and maintaining a substantial presence in every country is simply unattainable. For companies seeking to conduct research beyond their established geographic footprint, outsourcing presents a viable solution. This can be accomplished through various models, each entailing different degrees of internal control and partner responsibility.

Functional Service Provider (FSP) partnerships and Full-Service Outsourcing (FSO) are two overarching models frequently pursued by biotech and biopharma firms looking to outsource. Moreover, many clients opt for hybrid approaches that blend elements of both FSO and FSP models to align with their specific requirements.

In this whitepaper, authors will delve into several key topics, including:

• Why FSP arrangements serve as an ideal model for expanding clinical research operations into non-footprint countries.
• How FSP providers have the flexibility to tailor their services to precisely match the needs of their clients.
• The ways in which FSP support can effectively deliver on clients' primary objectives and foster global research excellence.
• Essential considerations for biotech and biopharma companies when selecting an FSP provider to support their endeavors in non-footprint countries.

Explore these strategic avenues to navigate the evolving clinical trial landscape and ensure the continued success of your research initiatives.